Key facts
- It has raised $6.5M; the latest was Seed Round ($6.5M) in Nov 2025.
- Notable investors include Red Cell Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Crux (US)
- ·The full record, as it builds
Funding rounds
No funding rounds for Crux (US) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Crux (US)
Developer of an artificial intelligence-driven performance marketing platform intended to help teams analyze advertising data and improve creative effectiveness. The company's platform connects to major ad accounts, aggregates cross-channel performance data, applies models for creative and audience analysis, generates insights and recommendations, supports creative ideation and experimentation workflows, integrates with existing marketing tools, and offers collaboration features, enabling performance marketers, growth teams, and agencies to manage campaigns more efficiently, test creatives systematically, and make data-driven decisions.
- Sector
- Business Products and Services (B2B)
- HQ
- Washington, DC, United States
- Website
- soon.cruxhealth.com/
- Ownership
- Privately Held (backing)
Crux (US) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Crux (US) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Crux (US) in its N-PORT filings yet. We sweep new filings monthly.